Ms project dates not updating

The agency believes that the patent is this basic structure of the compound, a number of new drugs will enter the market next year.Biogen Idec is developing treatments for multiple sclerosis drug BG-12 (dimethyl fumarate) is about to get FDA approval, the smooth realization of product changeovers.Finally, esomepazole carries two patents not expiring until 2018, and the trade press has wondered if these are an ace up Astra Zeneca’s patent lawyers’ sleeves.Cymbalta (duloxitine HCI), manufactured by Eli Lilly, is for the treatment of depression, generalized anxiety disorder, diabetic nerve pain, fibromylagia and chronic musculoskeletal pain. Marketed by Pfizer, celecoxib, a COX II inhibitor, is indicated for arthritis pain, other acute pain, and primary dysmenorrhea.Watch for generics on May 30, 2014, when the pediatric exclusivity expires.Sandostatin LAR (octreotide acetate for injectable suspension) by Novartis, is for the treatment of acromegaly syndrome, a hormonal disorder, and severe diarrhea and flushing associated with metastatic cancers. Eptifibatide, CAS# 188627-80-7, is an antiplatelet agent.

31, 2013 Estimated Global Sales 2012: $ 2.9 Billion Boehringer Ingelheim’s angiotensin II receptor antagonist telmisartan is approved to treat hypertension and reduce the risk of cardiovascular events.

Genzyme’s doxercalciferol, used to maintain consistent serum concentrations of vitamin D hormone, is approved for secondary hyperparathyroidism, and was acquired when the firm bought Bone Care International to gain products for kidney disease.

Trials testing the drug for osteoporosis and prostate cancer are also underway.

Also offered from LGM Pharma as a TEVA API (TAPI) product for compounding purposes, eptifibatide is also known by the brand name Integrilin, which is marketed by Merck.

With Merck’s patent for Integrilin due to expire on November 11, 2014, and an additional patent revision due to expire on May 5, 2015, this powerful drug is set to be a generic blockbuster. A selective non-peptide molecule, TEVETEN® is chemically described as the monomethanesulfonate of (E)-2-butyl-1 -(p-carboxybenzyl)-α-2-thienylmethylimid-azole-5 -acrylic acid.